SCHEMBL1151001

SCHEMBL1151001

CS(=O)(=O)c1cc(F)ccc1CCC=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 8/20 0.40
ADRA1A P35348 6/20 0.40
ADRA1B P35368 6/20 0.40
ADRA2A P08913 2/20 0.36
KDM4E B2RXH2 1/20 0.34
CCR2 P41597 1/20 0.34
PTGS2 P35354 2/20 0.33
SLC6A4 P31645 1/20 0.33
PTGS1 P23219 1/20 0.33
DDR1 Q08345 1/20 0.33
ADRA2C P18825 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
MEP1B Q16820 1/20 0.32
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1150730 0.83 KDM4E (0.38) ADRA1DADRA1AADRA1BKDM4ESLC6A4
SCHEMBL6077299 0.83 ADRA1D (0.43) ADRA1DADRA1AADRA1BADRA2AKDM4E
SCHEMBL1512139 0.81 ADRA1D (0.40) ADRA1DADRA1AADRA1BADRA2AKDM4E
SCHEMBL2556103 0.81 EDNRB (0.37) CCR2SMN1; SMN2
SCHEMBL27786995 0.80 ADRA1D (0.39) ADRA1DADRA1AADRA1BADRA2AKDM4E
SCHEMBL13180014 0.79 KDM4E (0.42) ADRA1DADRA1AADRA1BADRA2AKDM4E
SCHEMBL1150461 0.77 CA2 (0.48) ADRA1DADRA1AADRA1BADRA2AKDM4E
SCHEMBL6077312 0.77 ADRA1D (0.43) ADRA1DADRA1AADRA1BADRA2ACCR2
SCHEMBL17713483 0.76 ADRA1D (0.40) ADRA1DADRA1AADRA1BMEN1KMT2A
SCHEMBL4012771 0.76 ADRA1D (0.39) ADRA1DADRA1AADRA1BADRA2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 US disclosed
EP-2291377-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF Avexa Limited (AU) 2011-03-09 EP disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 US disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 WO disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF TPMT, DPYD, IMPDH1 ADRA1D 2810/4885ADRA1A 2397/4885ADRA1B 2326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.